In Washington, Arzeda, the Protein Design Company, entered into a joint development agreement with Amyris to design and develop novel enzymes for Amyris with unique functionalities, which Amyris will incorporate into their fermentation process to facilitate production of the target high value ingredients. This marks the second joint project between the parties. Amyris and Arzeda […]
In Washington state, BP and Arzeda entered a second extended collaboration agreement for developing a bio-process for production of a renewable chemical of high strategic and industrial interest to BP. After successful completion of the first phase of the project, BP and Arzeda chose to enter the second phase with the aim to accelerate progress […]
The question is being raised all over Silicon Valley — and increasingly around the world — if biotechnology is essentially a branch of information technology. 3D printing is one of those technologies that tests the boundaries between the digital and the physical worlds. Consider the images above you. On the upper left, an algorithm. On the […]
ENGAGE THE HYPER-DRIVE. Is everyone’s organism for making fuels, chemicals, materials, foods, flavors, fragrances and therapeutics — beautifully and slowly — heading for rapid obsolescence? “Everyone wants to make it faster,” notes Kytopen co-founder Cullen Buie. “Over the past 18 months, we discovered there’s a huge market for speed.” That’s one of the reasons why, […]
In Washington, Arzeda raised $12 million in a Series A round of funding, moving it forward on scaling up of their advanced protein design technology that is used for production of a range of chemicals and materials. The funding came from OS Fund, Bioeconomy Capital, Sustainable Conversion Ventures, and WRF Capital and will help beef […]
Arzeda’s proprietary technology combines targeted computational enzyme design and protein optimization with state-of-the-art metabolic bioengineering to create entirely novel designer cell factories capable of industry-scale chemical production. CEO Alex Zanghellini gave this illuminating overview of Arzeda’s breakthrough technology at ABLC 2017 in Washington, DC.
Arzeda’s proprietary technology combines targeted computational enzyme design and protein optimization with state-of-the-art metabolic bioengineering to create entirely novel designer cell factories capable of industry-scale chemical production. CEO Alex Zanghellini gave this overview of Arzeda’s breakthrough technology at ABLC Next in San Francisco.
At ABLC Next in California, Arzeda reached a major technical milestone with Amyris as a part of a Defense Advanced Research Projects Agency (DARPA) Technology Investment Agreement. Arzeda’s high-throughput, automated pipeline for protein engineering and pathway discovery has been validated by the production of two keystone molecules which will now be further optimized by Amyris. […]
In Washington state, Zymergen and Arzeda have signed a multi-year agreement to develop strains and processes to manufacture novel, high utility molecules and materials utilizing Arzeda’s pathway and enzyme design and Zymergen’s strain construction capabilities. “The development of new materials was a major driver of technological development over the course of the 20th century. Biology has the […]
In Switzerland, INVISTA Technologies and Arzeda Corp. announced a collaboration for the development of new technologies to enable novel bio-derived processes. The initial focus of the collaboration will be on the production of bio-derived butadiene. The agreement brings together complementary technologies: INVISTA’s capabilities in biotechnology and catalysis, and knowledge of the chemicals industry; and Arzeda’s unique […]
